Confronting Covid,Racism,and Addiction: The Association of Multidisciplinary Education and Research in Substance use and Addiction (Amersa)

Abstract

The COVID-19 pandemic, the ongoing opioid epidemic, rise in substance use, and social and political unrest in the US and globally has impacted how substance use-related health needs are addressed. These issues were driving forces in planning AMERSA's 44th annual conference. True to the multidisciplinary spirit, and with diversity goals and advocacy at the forefront of mind, “together we rise” became the beacon for the AMERSA 2020 conference. This commentary provides an overview of the conference proceedings, topics that were highly relevant for clinicians, educators, researcher, and advocates for change. Abstracts of paper and poster presentations are also provided (Supplemental Material).

Keywords

Multidisciplinary pandemic racism addiction

Get full access to this article

View all access options for this article.

References

Dobbs

, Fogger

SA.

Caught in the crossfire of the syndemic. J Addict Nurs. 2018;29(3):205–210.

Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality; 2019.

Leece

, Khorasheh

, Corace

, . Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review. BMJ Open. 2019;9(12):e032285.

Substance Abuse and Mental Health Services Administration (SAMHSA). FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed December 19, 2020.

Green

, Bratberg

, Finnell

DS.

Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.

Krawczyk

, Fingerhood

, Agus

Lessons from COVID 19: are we finally ready to make opioid treatment accessible?

J Subst Abuse Treat. 2020;117:108074.

Tierney

, Delaney

, Finnell

, Naegle

, Shatell

Make treatment accessible for opioid use disorder during the COVID-19 pandemic. Am Nurse. 2020. https://www.myamericannurse.com/make-treatment-accessible-for-opioid-use-disorder-during-the-covid-19-pandemic/. Accessed May 11, 2020.

Nagle

, Finnell

, Kaplan

, . Opioid crisis through the lens of social justice. Nurs Outlook. 2020; 68(5):682–684.

Matwick

, Woodgate

RL.

Social justice: a concept analysis. Public Health Nurs. 2017;34(2):176–184.

10.

Sohn

Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul Res Policy Rev. 2017;36(2):181–201.

11.

Pro

, Camplain

, Sabo

, Baldwin

, Gilbert

PA.

Substance abuse treatment in correctional versus non-correctional settings: analysis of racial/ethnic and gender differences. J Health Disparities Res Pract. 2018;12(3):1.

12.

Substance Abuse and Mental Health Services Administration (SAMHSA). The Opioid Crisis and the Black/African American Population: An Urgent Issue. Publication No. PEP20-05-02-001. Office of Behavioral Health Equity; 2020.

13.

AMERSA. 2020. AMERSA issues solidarity statement 06.11.20. 2020. https://amersa.org/about-us/advocacy-statements/. Accessed December 19, 2020.

14.

Ahamad

, Paxton

, Brar

, . Risk Mitigation in the Context of Dual Public Health Emergencies. 2020. https://www.bccsu.ca/wp-content/uploads/2020/04/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies-v1.5.pdf. Accessed December 19, 2020.

15.

Montfiore Buprenorphine Treatment Network https://www.montefiore.org/buprenorphine. Accessed December 19, 2020.

16.

National Sobering Collaborative https://nationalsobering.org/. Accessed December 19, 2020.

17.

National Harm Reduction Coalition https://harmreduction.org/. Accessed December 19, 2020.

18.

Compton

, Wasser

, Cheatle

Increased experimental pain sensitivity in chronic pain patients who developed opioid use disorder. Clin J Pain. 2020;36(9):667–674.

19.

Compton

. Acute pain management for patients receiving medication-assisted therapy. AACN Adv Crit Care. 2019;30(4):335–342.

20.

Wakeman

, Barnett

ML.

Primary care and the opioid-overdose crisis – buprenorphine myths and realities. N Engl J Med. 2018;379(1):1–4.

21.

Haffajee

, Bohnert

ASB

, Lagisetty

PA.

Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S242. Jun

22.

NIDA. 2019, July 16. Access to Addiction Services Differs by Race and Gender. https://www.drugabuse.gov/about-nida/noras-blog/2019/07/access-to-addiction-services-differs-by-race-gender. Accessed December 19, 2020.

23.

Bourgois

, Holmes

, Sue

, Quesada

Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Acad Med. 2017;92(3):299–307.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

1.84 MB

0.00 MB